

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-A**

---

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR 12(g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

**Urovant Sciences Ltd.**

(Exact name of registrant as specified in its charter)

---

**Bermuda**  
(State of incorporation or organization)

**Not Applicable**  
(I.R.S. Employer Identification No.)

**Suite 1, 3rd Floor**  
**11-12 St. James's Square**  
**London SW1Y 4LB**  
**United Kingdom**  
(Address of principal executive offices)

**Not Applicable**  
(Zip Code)

**Securities to be registered pursuant to Section 12(b) of the Act:**

**Title of each class  
to be so registered**  
**Common Shares \$0.000037453 par value per share**

**Name of exchange on which  
each class is to be registered**  
**The Nasdaq Stock Market LLC**

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

**Securities Act registration statement or Regulation A offering statement file number to which the form relates:**  
**333-226169**

**Securities to be registered pursuant to Section 12(g) of the Act:**  
**None.**

---

---

---

**Item 1. Description of Registrant's Securities to be Registered.**

Urovant Sciences Ltd. (the "Registrant") hereby incorporates by reference the description of its Common Shares, \$0.000037453 par value per share, to be registered hereunder set forth in the section titled "Description of share capital" in the Registrant's Registration Statement on Form S-1 (File No. 333-226169), as originally filed with the U.S. Securities and Exchange Commission (the "Commission") on July 13, 2018, as subsequently amended (the "Registration Statement"), and in the related prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

UROVANT SCIENCES LTD.

Date: September 20, 2018

By: /s/ Keith A. Katkin

Name: Keith A. Katkin

Title: Principal Executive Officer